- Home
- FVR vs IMAB Comparison
FVR vs IMAB Comparison
Compare FVR & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVR
- IMAB
- Stock Information
- Founded
- FVR 2016
- IMAB 2014
- Country
- FVR United States
- IMAB United States
- Employees
- FVR N/A
- IMAB N/A
- Industry
- FVR
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FVR
- IMAB Health Care
- Exchange
- FVR NYSE
- IMAB Nasdaq
- Market Cap
- FVR 227.7M
- IMAB 200.9M
- IPO Year
- FVR 2024
- IMAB 2020
- Fundamental
- Price
- FVR $12.84
- IMAB $2.11
- Analyst Decision
- FVR Hold
- IMAB Strong Buy
- Analyst Count
- FVR 5
- IMAB 3
- Target Price
- FVR $16.80
- IMAB $6.33
- AVG Volume (30 Days)
- FVR 221.8K
- IMAB 388.6K
- Earning Date
- FVR 08-13-2025
- IMAB 05-15-2025
- Dividend Yield
- FVR 6.70%
- IMAB N/A
- EPS Growth
- FVR N/A
- IMAB N/A
- EPS
- FVR N/A
- IMAB N/A
- Revenue
- FVR $60,901,000.00
- IMAB N/A
- Revenue This Year
- FVR $17.29
- IMAB N/A
- Revenue Next Year
- FVR $8.41
- IMAB N/A
- P/E Ratio
- FVR N/A
- IMAB N/A
- Revenue Growth
- FVR 15.85
- IMAB N/A
- 52 Week Low
- FVR $10.61
- IMAB $0.60
- 52 Week High
- FVR $19.76
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- FVR N/A
- IMAB 49.47
- Support Level
- FVR N/A
- IMAB $2.01
- Resistance Level
- FVR N/A
- IMAB $2.25
- Average True Range (ATR)
- FVR 0.00
- IMAB 0.13
- MACD
- FVR 0.00
- IMAB -0.03
- Stochastic Oscillator
- FVR 0.00
- IMAB 25.00
About FVR FRONTVIEW REIT INC
FrontView REIT Inc is an internally managed net-lease REIT that is experienced in acquiring, owning, and managing out parcel properties that are net-leased to a diversified group of tenants. The tenants of the company include service-oriented businesses, such as restaurants, cellular stores, financial institutions, automotive stores and dealers, medical and dental providers, pharmacies, convenience and gas stores, car washes, home improvement stores, grocery stores, professional services as well as general retail tenants.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).